{"classes":[{"categories":[{"measurements":[{"comment":"The 95% confidence interval upper limit has not been reached. (insufficient number of participants with events)","groupId":"OG000","lowerLimit":"5.6","upperLimit":"NA","value":"12.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Time from registration to death due to any cause, assessed up to 1 year. The distribution of survival time will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 650 mg Acetaminophen and 50 mg Benadryl orally 30 minutes prior to MV-NIS then receive MV-NIS IV over 1 hour on day 1.","id":"OG000","title":"Phase II (Acetaminophen + Benadryl + MV-NIS)"}],"paramType":"MEDIAN","populationDescription":"Only phase II patients who completed the study are included in this analysis. Phase II Cohort A and Phase II Cohort B were combined for this analysis due to accrual terminating early in Cohort B.","reportingStatus":"POSTED","timeFrame":"Time from registration to death due to any cause, assessed up to 1 year","title":"Overall Survival (Phase II)","type":"SECONDARY","unitOfMeasure":"months"}